The COVID-19 pandemic has inflicted loss of human life, serious illness, and social and economic disruption across the European Union (EU) and worldwide. There are currently no authorised vaccines for COVID-19 in EU/EEA countries.
Safe and effective vaccines for COVID-19 are needed to protect individuals from becoming ill, especially healthcare professionals and vulnerable populations, such as older people and people with long-term diseases.
The European Commission and EU agencies are making every effort to support the accelerated research and development of COVID-19 vaccines.
This aims to ensure that these vaccines are available as early as possible, once they are proven to be safe and effective.
The EU strategy for COVID-19 vaccines, launched by the European Commission, intends to:
- ensure high quality, safe and effective COVID-19 vaccines;
- secure rapid access to these vaccines for Member States and their populations.
This strategy reflects the global solidarity effort to ensure equitable access to an affordable vaccine as early as possible.
In preparation for COVID-19 vaccines, the European Commission has also set out key preparedness elements for Member States to take into consideration for their COVID-19 vaccination strategies.
For full details, see Preparedness for COVID-19 vaccination strategies and vaccine deployment
For more general information on vaccination see:
There are currently no authorised vaccines for COVID-19 in EU/EEA countries. The European Medicines Agency (EMA) is working hard to ensure that safe and effective vaccines reach the public as soon as possible.
COVID-19 is the disease associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 is a new strain of coronavirus that had not been identified in humans prior to December 2019. There are different types of coronaviruses and, although they mostly circulate among animals, some can also infect humans.